Abstract:Cellular senescence describes an irreversible growth arrest characterized by distinct morphology, gene expression pattern, and secretory phenotype. The final or intermediate stages of senescence can be reached by different genetic mechanisms and in answer to different external and internal stresses. It has been maintained in the literature but never proven by clearcut experiments that the induction of senescence serves the evolutionary purpose of protecting the individual from development and growth of cancers. This hypothesis was recently scrutinized by new experiments and found to be partly true, but part of the gene activities now known to happen in senescence are also needed for cancer growth, leading to the view that senescence is a double-edged sword in cancer development. In current cancer therapy, cellular senescence is, on the one hand, intended to occur in tumor cells, as thereby the therapeutic outcome is improved, but might, on the other hand, also be induced unintentionally in non-tumor cells, causing inflammation, secondary tumors, and cancer relapse. Importantly, organismic aging leads to accumulation of senescent cells in tissues and organs of aged individuals. Senescent cells can occur transiently, e.g., during embryogenesis or during wound healing, with beneficial effects on tissue homeostasis and regeneration or accumulate chronically in tissues, which detrimentally affects the microenvironment by de- or transdifferentiation of senescent cells and their neighboring stromal cells, loss of tissue specific functionality, and induction of the senescence-associated secretory phenotype, an increased secretory profile consisting of pro-inflammatory and tissue remodeling factors. These factors shape their surroundings toward a pro-carcinogenic microenvironment, which fuels the development of aging-associated cancers together with the accumulation of mutations over time. We are presenting an overview of well-documented stress situations and signals, which induce senescence. Among them, oncogene-induced senescence and stress-induced premature senescence are prominent. New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors.

Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy

Cellular senescence in cancer: clinical detection and prognostic implications

Cellular senescence: the good, the bad and the unknown

The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy

Cellular senescence in cancer: molecular mechanisms and therapeutic targets

Cellular senescence and SASP in tumor progression and therapeutic opportunities

Cellular Senescence and Cancer Progression

Cellular senescence in cancer: from mechanisms to detection

Cellular Senescence in the Lung: The Central Role of Senescent Epithelial Cells

Cellular Senescence and Anti-Cancer Therapy.

Cellular Senescence: Mechanisms and Therapeutic Potential

Cellular senescence: from physiology to pathology

Cellular Senescence: Mechanisms, Morphology, and Mouse Models

Senescence in cancer: Advances in detection and treatment modalities

Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs

Cellular senescence: A reflection of normal growth control, differentiation, or aging?

Cellular Senescence: Defining a Path Forward

Pan-cancer characterization of cellular senescence reveals its inter-tumor heterogeneity associated with the tumor microenvironment and prognosis

Comprehensive assessment of cellular senescence in the tumor microenvironment

Cellular senescence: when bad things happen to good cells

Unmasking senescence: context-dependent effects of SASP in cancer